NovoCure Ltd — Director's Dealing 2024

Nov 4, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2024-11-01

Reporting Person: Leonard Frank X (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-01	Ordinary Shares	S	598.00	$15.9377	Disposed	161236.00	Direct

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: This transaction was executed in multiple trades at prices ranging from $15.88 USD to $15.9603 USD; the price reported above reflects the weighted average sale price.